Wearable sensors track stress and sleep during money and news turbulence
Watches body stress and sleep with wearable devices in adults during market swings.
Key facts
- Who runs it
- Truway Health, Inc.
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- NeuroFinance Human Stress Trial During Financial and Informational Volatility
- Status
- Enrolling by invitation
- People taking part
- 2,500 people, planned
- Started
- 15 Jul 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Observational, 4 groups
- Treatments tested
- Wearable Physiologic Monitoring Platform
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who will wear health-tracking devices at home. It studies how financial and news stress affects the body. Healthy people and people with stress symptoms can join.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- No disease is needed. People with self-reported stress-related symptoms can also join.
Main reasons for not taking part
- Not able or willing to give informed consent
- Not able to use wearable devices or follow remote monitoring
- Active medical or psychiatric instability, as judged by the study team
- Currently in prison or living in an institution that limits free choice
- Taking part in another treatment trial that could disturb the body measurements
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adults age 18 years and older
- Ability to provide informed consent
- Willingness and ability to comply with study procedures and remote monitoring requirements
- Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation
- Willingness to utilize wearable physiologic monitoring technologies during the study period
- Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible
- Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled
- Ability to read and understand English-language consent and study materials
Who cannot take part
- Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity
- Any condition that would significantly impair safe study participation as determined by the study investigators
- Individuals unable or unwilling to provide informed consent
- Individuals unable to comply with remote monitoring procedures or wearable device usage requirements
- Current incarceration or institutionalization limiting voluntary participation
- Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes
Where in United States
- Truway Health, Inc.New York, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
The 4 groups in the trial
- Retail Investors / Active Traders Cohort
Participants actively engaged in retail equity, options, futures, cryptocurrency, or other financial trading activities who are exposed to frequent market volatility and information-driven financial stress environments.
Treatment: Wearable Physiologic Monitoring Platform
- Financial Professionals Cohort
Participants employed in financial services, institutional trading, investment banking, hedge funds, private equity, fintech, wealth management, or related high-stress financial occupations.
Treatment: Wearable Physiologic Monitoring Platform
- General Population Control Cohort
Participants from the general population with varying levels of financial market exposure serving as a comparative baseline cohort for physiologic and behavioral stress-response analysis.
Treatment: Wearable Physiologic Monitoring Platform
- High Digital Media Exposure Cohort
Participants with elevated exposure to financial news, algorithmic media feeds, social media platforms, and information-intensive digital environments associated with financial and geopolitical stress signaling.
Treatment: Wearable Physiologic Monitoring Platform
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)
- Plain-language title
- Wearable sensors track stress and sleep during money and news turbulenceGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 August 2026